A new methadone regulation was proposed by the FDA in April 1972 and finally published on December 15, 1972 (37 FR 26790). Although they were amended several times over the next two decades, they established the basic DHHS framework that still exists for the regulation of methadone and represents the third level of regulation, in addition to the traditional regulatory approaches historically followed by the FDA and DEA (and their predecessors). The regulation removed methadone from general distribution and established controls on its use, literally on a patient-by-patient basis, through medical records and treatment programs with characteristics prescribed in the regulation. When they are able to work, untreated heroin addicts are often so busy satisfying their addiction that they are unable to effectively manage their responsibilities in the workplace. On the other hand, it is clear that many heroin addicts, when stabilized in methadone treatment programs, are able to find and maintain employment, expand access to health resources and services, and support themselves and their families. Visits by the study director, accompanied by one or more committee members, to New York and Boston included meetings with methadone program administrators in those states. IOM asked the New York Committee of Methadone Program Administrators (COMPA) to provide feedback on the regulations, which COMPA did to the great benefit of the committee. Similarly, state authorities were invited to comment by Commissioner Marguerite Saunders of the New York Bureau of Alcoholism and Drug Abuse and a member of the committee, and complied with about half of the cases. From the mid to late 1960s, when Dole`s discoveries sparked interest among researchers and clinicians, the FDA, for its part, showed little interest in methadone use.

He simultaneously opposed the filing of a marketing authorization application for methadone on the grounds that there was no supporting scientific data developed under the INDs and did little to promote IND applications, with some FDA officials expressing skepticism that Dole had achieved the claimed results (Besteman interview). Like all medications used in drug treatment (MAT), methadone is intended to be prescribed as part of a comprehensive treatment plan that includes counseling and participation in social support programs. Mark Sinatra prevented a couple from leaving a methadone clinic in Queens. Three studies reviewed below illustrate these points, although several large-scale evaluations of methadone maintenance yield essentially the same results (Dole, Nyswander, 1968; Gears, Schweitzer, 1974; Hubbard, Marsden, 1986; Sells, Demaree et al., 1986; Ball, Ross, 1991). In the most detailed review of methadone maintenance treatment programs to date, Ball and Ross (1991) found that maintaining methadone was associated with a significant reduction in illicit drug use, and in crime in particular. They evaluated twelve methadone maintenance programs in three northeastern cities using two samples of newly recruited or stabilized patients, each sample being taken over a five-year period. The main metabolic pathway involves N-demethylation by CYP3A4 in the liver and intestines to obtain 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). [4] [68] This inactive product, along with the inactive 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (PMME), which is produced by a second N-demethylation, are detectable in urine from methadone ingestion. The current rules aim to limit the distribution of methadone for therapeutic purposes and to establish and enforce standards for medical methadone care to prevent the diversion of methadone to non-medical channels and to exclude inappropriate individuals from methadone treatment. In the Committee`s view, these rules are based on the belief that the social risks are so great and the societal benefits so limited that exceptional controls are needed that go beyond those applicable to any other therapeutic drug in the United States. This belief may have been valid and useful in the late 1960s and early 1970s, when the experience of methadone was not extensive and the social risks associated with heroin use seemed largely confined to the addicts themselves. It wasn`t until 1947 that the drug received the generic name «methadone» by the Council on Pharmacy and Chemistry of the American Medical Association.

Since the patent rights of the I.G. Farben Group and Farbwerke Hoechst were no longer protected, any pharmaceutical company interested in the formula could acquire the rights to the commercial production of methadone for only one dollar (MOLL 1990). The Committee identified three objectives that guide the use of methadone in the treatment of opioid dependence. While the relative importance of these objectives has evolved over time, the Committee believes that these three objectives should continue to inform policy. Once an appropriate dose (usually 60 to 120 mg daily; see Chapter 7 for a discussion of dosage) has been established, patients receiving methadone show improvement in a number of outcomes (Dole, Nyswander, 1968; Gears, Schweitzer, 1974; Sells, Demaree et al., 1979; Dole, Nyswander et al., 1982; Hubbard, Marsden et al., 1986). First, the use of all illicit drugs is declining. The frequency of heroin use drops to an average of less than 40% of pre-treatment levels in the first year of treatment, as some addicts stop completely and others only slightly reduce their use. Further reductions are achieved for patients who continue treatment for two years or more and eventually achieve an average of 15% of the pre-treatment level (Sells, Demaree et al., 1979; Cummings, 1979; Newton, 1979; Rounsaville, Weissman et al., 1982; Woody, Luborsky et al., 1983; Khantzian, Treece, 1985; Wrangle, Corty, Ball, 1987; McNeil-Lehrer, 1988; Ball, Ross, 1993).